The French Endocrine Society suggests that the development of diabetes during ICIs treatment with anti-PD-1 or PD-L1 is not a contraindication for continued ICsI, but when the situation is severe, ICIs treatment can be delayed for a few days. The gene discussed is CD274; the disease is diabetes mellitus.